DOCSLIB.ORG

Moneyball Medicine Discusses Some of the Remarkable Innovations That Are Developing Across the Healthcare Industry

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Moneyball Medicine Discusses Some of the Remarkable Innovations That Are Developing Across the Healthcare Industry MoneyBall Medicine discusses some of the remarkable innovations that are developing across the healthcare industry. Harry and Malorye provide readers with a front row seat to the most important emerging healthcare system challenges—and opportunities—of our time. We started Flatiron because we wanted to ensure that all cancer patients—not just those with the means and resources—have access to the same cutting-edge research. It is our hope that this book will stimu- late discussions around the value of next-generation technology in healthcare so that the industry can continue to innovate. Zach Weinberg Cofounder, COO, and President Flatiron Health MoneyBall Medicine puts you at the center of healthcare’s new frontier where medicine, tech- nology, information, and business are converging and advancing with unprecedented speed and importance. The stakes could not be higher, and I recommend this book for anyone interested in learning more about this truly disruptive revolution in the ever-changing healthcare landscape. Eric Schadt, PhD Dean for Precision Medicine, Mount Sinai Health System Professor, Genetics and Genomic Sciences at Mount Sinai The political turbulence focused on what comes next for Medicaid, Medicare, and the Affordable Care Act (Obamacare) public exchange products simply reinforces the fundamentals of healthcare in the United States. Increased access, increased value, and better patient experience will be keys for all successful stakeholders. In MoneyBall Medicine, Harry and Malorye describe the unique confluence of entrepreneurial innovation and the many entrenched and evolving healthcare components of the healthcare supply chain, and defines the parameters that predict who will win and who will lose. Glenn D. Steele, Jr., MD, PhD Chairman of xG Health Solutions Vice-Chair of Health Transformation Alliance Former CEO of Geisinger Health System Data, data everywhere. Well, historically it’s been everywhere but in healthcare, where our indus- try has been laggards in distributing, sharing, synthesizing, and analyzing data to make deci- sions for researchers, physicians, patients, and insurers. MoneyBall Medicine thoughtfully walks us through the change in healthcare, which has already commenced. Data will finally take center stage, especially in cancer care. Mike Pellini, MD, MBA Chairman and Former Chief Executive Officer Foundation Medicine The explosive force that’s transforming healthcare is digital. Harry and Maloyre have aptly cap- tured and described this tidal wave in a compelling compendium of examples and interviews. MoneyBall Medicine lays the foundation for understanding how new types of data will change the way we discover medicines, measure their impact, deploy, deliver, and even replace them. Christine Lemke Cofounder and President Evidation Health, Inc. We are all now living in a world of data-driven medicine. MoneyBall Medicine is a really important source for navigating in this new world. Rory Riggs Royalty Pharma—Cofounder and Chairman of the Investment Committee Locus Analytics—CEO Syntax—CEO As a citizen scientist activist and the mom of children with a genetic condition, I welcome the effect on healthcare of meaningful data, carefully analyzed and appropriately utilized. MoneyBall Medicine artfully traverses the ever-evolving dynamic landscape and focuses in on the various levers and fulcrums that might make the difference, all the while keeping the consumer in the center. Sharon Terry President and Chief Executive Officer Genetic Alliance We face a perfect storm: a medical profession, reluctant to emerge from principles of apprentice- ship and autonomous practice to evidence-based approaches, still largely rewarded by volume-based payments, and a healthcare industry, which has accumulated legacy structures never designed for efficiency and interoperability. The combination has resulted in an increasingly unaffordable U.S. healthcare delivery system, which covers only part of the populous and has outcomes at or below the level of other civilized countries. Expedient and systematic solutions are further impeded by privacy and safety concerns, which have resulted in well-intended, but impractical legislation and heavy regu- latory burden. Glorikian and Branca’s inspiring book highlights real (entrepreneurial) opportunity to use the power of multisource Big Data and emerging analytic approaches to get out of this misery and revolutionize the way healthcare is delivered to ever more data-conscious, engaged patients. Christoph Wald, MD, PhD, MBA, FACR Chairman, Department of Radiology and President of the Medical Staff Lahey Hospital and Medical Center Professor of Radiology, Tufts University Medical School Data has become a significant strategic resource in healthcare. Just as sports, financial services, retail, and virtually all other industries have been shaped by data and analytics, so too will health- care. Harry and Malorye have done an exceptional job of documenting and analyzing this remark- able transition in the largest and most complex sector in our economy—healthcare. John Glaser, PhD Vice President Population Health and Global Strategy Cerner Corp. The pace of scientific development is proceeding unlike any other time in the history of healthcare. Precision Medicine is becoming a reality. MoneyBall Medicine provides a compelling overview of how new technologies, diagnostic tests, and drugs are being introduced at record speed, and how these advancements and the resulting access to increasing amounts of patient-specific data are rapidly transforming the way healthcare can and will be delivered. Jennifer Levin Carter MD, MPH Founder and Chief Medical Officer N-of-One, Inc. The future of healthcare is inevitably data driven. As our ability to collect, sort, and analyze data improves, the predictability of what people need is enhanced. This will result in more precise medicine, with better customized and personalized treatment plans for our patients. This book is ahead of its time, bringing together concepts of new innovations aimed at improving healthcare delivery. Kathryn Teng, MD, MBA Physician Executive Leader and Division Chief MetroHealth Medical Center The convergence of Big Data and artificial intelligence is changing the paradigm for the entire healthcare sector—MoneyBall Medicine is a MUST-READ book for entrepreneurs hoping to make an impact in this complex ecosystem. Dekel Gelbman, MBA Chief Executive Officer FDNA If you want to understand the future of healthcare, you need to read MoneyBall Medicine. Paralleling the data-driven transformation of baseball, Harry Glorikian and Malorye Allison Branca delve into the data and analytic trends that are revolutionizing healthcare. As this book articulately describes, it’s only through collecting, connecting, and understanding data that we will arrive at a patient- centered healthcare system. Grounded in firsthand accounts, rich in detail, and accessible to practi- tioners and experts alike, MoneyBall Medicine is a great read and worthwhile investment. Robert Metcalf, MBA Chief Executive Officer Concert Genetics Harry and Malorye’s book provides a comprehensive look at how data is rapidly becoming the currency of modern medicine and how this is fueling a market comprised of a diverse set of tech- nologies, approaches, and business opportunities. Notably, of course, the goal must be to maximize the rate of exchange, from data to true clinical value. The book recognizes the diversity and lack of synchrony among the critical market factors that impact this exchange, that is, payers; providers; patients (needs, expectations, and hopes); physicians; and pharma. By identifying and describing the concerns and priorities of this network, this book can serve as a solid base for advancing toward addressing an even bigger opportunity … that of the unstated and unmet clinical needs that we don’t currently even consider. Michael N. Liebman, PhD Managing Director, IPQ Analytics, LLC Adjunct Professor of Pharmacology and Physiology, Drexel College of Medicine The U.S. healthcare system is undergoing sweeping change with profound implications for all Americans, and the change is not waiting for Congress or the White House to determine its fate. MoneyBall Medicine defines this pivotal time as we live it, showing how new expectations shape our healthcare, and how each of us as individuals will be changed by it too. I can’t think of a more compelling and important book for future historians, who will no doubt wonder how our health- care system was so dramatically transformed in the early twenty-first century. Leah F. Binder, MA, MGA President and CEO The Leapfrog Group “If the difference between evolution and revolution is the speed of change, then healthcare is now in the mode of revolutionary change,” say authors Harry Glorikian and Malorye Allison Branca in MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market. Healthcare spending in the United States today is simply unsustainable. In this book, Glorikian and Branca reveal promising trends that will revolutionize healthcare. I believe their visions are spot on. If you want a glimpse into the future, read this book. It’s fascinating and very well documented. Tom Emerick Former VP of Global Benefits at Walmart Population Health Consultant Cofounder of EdisonHealth Coauthor of Cracking Health Costs and An Illustrated Guide to Personal Health MoneyBall Medicine takes the reader on a deliberately pragmatic insider’s journey of how raw, objective, hard data is already becoming the
Load more

Recommended publications
  • Guardant Health, Inc. Form 8-K Current Event Report Filed 2019-01
    SECURITIES AND EXCHANGE COMMISSION FORM 8-K Current report filing Filing Date: 2019-01-07 | Period of Report: 2019-01-07 SEC Accession No. 0001628280-19-000132 (HTML Version on secdatabase.com) FILER Guardant Health, Inc. Mailing Address Business Address 505 PENOBSCOT DR. 505 PENOBSCOT DR. CIK:1576280| IRS No.: 454139254 | State of Incorp.:DE | Fiscal Year End: 1231 REDWOOD CITY CA 94063 REDWOOD CITY CA 94063 Type: 8-K | Act: 34 | File No.: 001-38683 | Film No.: 19512177 855-698-8887 SIC: 8071 Medical laboratories Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2019 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 0001-576280 45-4139254 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation or organization) File Number) Identification No.) 505 Penobscot Dr. Redwood City, California 94063 (Address of principal executive offices) (Zip Code) 855-698-8887 (Registrant’s telephone number, include area code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under
    [Show full text]
  • Guardant Health, Inc. Form 10-Q Quarterly Report Filed 2021-08-05
    SECURITIES AND EXCHANGE COMMISSION FORM 10-Q Quarterly report pursuant to sections 13 or 15(d) Filing Date: 2021-08-05 | Period of Report: 2021-06-30 SEC Accession No. 0001576280-21-000080 (HTML Version on secdatabase.com) FILER Guardant Health, Inc. Mailing Address Business Address 505 PENOBSCOT DR. 505 PENOBSCOT DR. CIK:1576280| IRS No.: 454139254 | State of Incorp.:DE | Fiscal Year End: 1231 REDWOOD CITY CA 94063 REDWOOD CITY CA 94063 Type: 10-Q | Act: 34 | File No.: 001-38683 | Film No.: 211148786 855-698-8887 SIC: 8071 Medical laboratories Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 _____________________ GUARDANT HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) _____________________ Delaware 45-4139254 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 505 Penobscot Dr. Redwood City, California, 94063 Registrant’s telephone number, including area code: (855) 698-8887 _______________ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Arizona Fall League Opens 17Th Season
    For Immediate Release Monday, October 6, 2008 Arizona Fall League Opens 17th Season Phoenix, Arizona — The Arizona Fall League, known throughout professional baseball as a “finishing school” for Major League Baseball’s elite prospects, begins its 17th season on Tuesday, October 7 with three games — Surprise Rafters @ Peoria Javelinas (12:35 p.m.), Mesa Solar Sox @ Phoenix Desert Dogs (12:35 p.m.), and Peoria Saguaros @ Scottsdale Scorpions (7:05 p.m.). The Future Of The six-team league, owned and operated by Major League Baseball, plays six days Major League per week (Monday-Saturday) in five Cactus League stadiums (Mesa, Peoria, Phoenix, Baseball Now Scottsdale, Surprise) in the Phoenix metropolitan area. This year’s schedule concludes with a championship game on Saturday, November 22 at Scottsdale Stadiium. The mid- Facts season “Rising Stars Game” will be played on Friday, October 24 at Surprise Stadium. • Over 1,600 former Fall The Phoenix Desert Dogs, playing in the National Division this season, seek their Leaguers have reached the fifth consecutive Arizona Fall League title with players from the Arizona Diamondbacks, major leagues Colorado Rockies, Minnesota Twins, Oakland Athletics, and Toronto Blue Jays. • 413 Ex-AFLers On 2008 MLB Opening-Day Rosters American Division • 136 MLB All-Stars Mesa Solar Sox Peoria Saguaros Scottsdale Scorpions including 36 in 2008 (Hohokam Stadium) (Peoria Stadium) (Scottsdale Stadium) •Atlanta Braves •Chicago White Sox •Boston Red Sox • 5 MLB MVPs •Jason Giambi •Chicago Cubs •New York Mets •Houston
    [Show full text]
  • Exhibit Hall
    Exhibit Hall VHQ7200 VHQ7300 VHQ7500 VHQ7800 VHQ1900 VHQ1200 VHQ1300 VHQ1800 VHQ2400 VHQ2500 VHQ2600 VHQ2900 VHQ3000 VHQ3100 VHQ3200 VHQ3500 VHQ3600 VHQ3700 VHQ4100 VHQ4200 VHQ4300 VHQ4400 VHQ4500 VHQ4600 VHQ5100 VHQ5400 VHQ600 VHQ800 VHQ3800 VHQ5500 VHQ5600 VHQ5700 VHQ7000 3M Health Clinical IMO-Intelligent IMO-Intelligent Vocera Vocera Cisco GE athenahealth, athenahealth, InterSystems InterSystems Greenway Cerner AGFA Change Siemens Healthcare Communications, Communications, Inc. Epic Information CloudWave Allscripts Informatica Architecture, Medical Medical WellSky Google Google Systems, Inc. Healthcare Inc. Corporation Corporation Corporation Elsevier HealthCare Healthcare Healthineers Growth Partners Objects Inc. Objects Inc. Optum IBM Inc. Inc. Systems Health LLC Cloud Cloud MP148 MP158 MP168 MP15 MP35 MP137 Greenway Transcend Audacious ClearDATA Verato Inquiry, Inc Health Insights temp_47697 7293 7392 7393 7492 7493 7592 7593 7692 7693 7792 7793 7892 7893 7992 7993 8092 8093 8192 8193 8292 8293 MP127 LabCorp MP147 MP157 MP167 MP14 MP34 MP51 MP63 1493 1592 1593 1692 1693 1793 1892 1893 1993 2092 2193 2293 2392 2393 2493 2593 2693 2892 3592 3993 4092 4093 4293 4393 4492 4693 4793 4993 5092 5192 5393 5492 5493 5592 5693 5793 5892 5893 5992 6293 6793 6892 6993 888-112 888-113 891 991 1391 2790 2789 3291 3390 3391 3491 4190 4191 4390 4491 4591 4790 4890 4891 5089 5191 5291 5390 5591 6391 CI Security 6891 7090 888-105 888-106 888-108 888-109 Two Point GRM Superior Bridge Pieces Tonic Transcend RxRevu, Amazon Web Greenway Symantec Cisco CipherLab Devon Luma Travers Zoom Video 2089 Etiometry, Lightning Bolt Nexlink HEF 2889 2989 3189 3588 Beanstock TeamUC Harris Holadoctor, Decisio 6489 6689 By Information Softrams Conversions, Communications Rosettahealth Business Relatient GravitasMD ER2 Densitas Alteryx Inc Patient HealthLynked Critical Technologies Systems, Inc.
    [Show full text]
  • 2008 Topps Baseball Card Set Checklist
    2008 TOPPS BASEBALL CARD SET CHECKLIST 1 Alex Rodriguez 2 Barry Zito 3 Jeff Suppan 4 Rick Ankiel 5 Scott Kazmir 6 Felix Pie 7 Mickey Mantle 8 Stephen Drew 9 Randy Wolf 10 Miguel Cabrera 11 Yorvit Torrealba 12 Jason Bartlett 13 Kendrys Morales 14 Lenny DiNardo 15 Magglio Ordonez / Ichiro Suzuki / Placido Polanco 16 Kevin Gregg 17 Cristian Guzman 18 J.D. Durbin 19 Robinson Tejeda 20 Daisuke Matsuzaka 21 Edwin Encarnacion 22 Ron Washington MG 23 Chin-Lung Hu RC 24 Alex Rodriguez / Magglio Ordonez / Vladimir Guererro 25 Kazuo Matsui 26 Manny Ramirez 27 Bob Melvin MG 28 Kyle Kendrick 29 Anibal Sanchez 30 Jimmy Rollins 31 Ronny Paulino 32 Howie Kendrick 33 Joe Mauer 34 Aaron Cook 35 Cole Hamels 36 Brendan Harris 37 Jason Marquis 38 Preston Wilson 39 Yovani Gallardo 40 Miguel Tejada 41 Rich Aurilia 42 Corey Hart Compliments of BaseballCardBinders.com© 2019 1 43 Ryan Dempster 44 Jonathan Broxton 45 Dontrelle Willis 46 Zack Greinke 47 Orlando Cabrera 48 Zach Duke 49 Orlando Hernandez 50 Jake Peavy 51 Erik Bedard 52 Trevor Hoffman 53 Hank Blalock 54 Victor Martinez 55 Chris Young 56 Seth Smith RC 57 Wladimir Balentien RC 58 Matt Holliday / Ryan Howard / Miguel Cabrera 59 Grady Sizemore HL 60 Jose Reyes 61 Alex Rodriguez / Carlos Pena / David Ortiz 62 Rich Thompson RC 63 Jason Michaels 64 Mike Lowell 65 Billy Wagner 66 Brad Wilkerson 67 Wes Helms 68 Kevin Millar 69 Bobby Cox MG 70 Dan Uggla 71 Jarrod Washburn 72 Mike Piazza 73 Mike Napoli 74 Garrett Atkins 75 Felix Hernandez 76 Ivan Rodriguez 77 Angel Guzman 78 Radhames Liz RC 79 Omar Vizquel 80
    [Show full text]
  • Monitoring Trace Levels of Ctdna Using Integration of Variant Reads
    Monitoring trace levels of ctDNA using 1 integration of variant reads 2 3 Jonathan C. M. Wan 4 Supervisor: Dr Nitzan Rosenfeld 5 6 Cancer Research UK Cambridge Institute 7 8 University of Cambridge This dissertation is submitted for the degree of 9 Doctor of Philosophy 10 Trinity College May 2019 11 Abstract 12 In patients with early-stage cancer, ctDNA detection rates can be low due to the presence of 13 few or no copies of any individual mutation in each sample. Sensitivity may be increased 14 by collecting larger plasma volumes, but this is not feasible in practice. Although cancers 15 typically have thousands of mutations in their genome, previous analyses measured only 16 individual or up to 32 tumour-specific mutations in plasma. 17 Here, we demonstrate that sensitivity can be greatly enhanced for any given input DNA 18 mass by analysing a large number of mutations via sequencing. We sequenced in plasma 2 4 19 10 -10 mutated loci per patient, using custom capture panels, whole exome (WES) or 20 whole genome sequencing (WGS). We developed a method for INtegration of VAriant Reads 21 (INVAR) that aggregates reads carrying tumour mutations across multiple mutant loci, and 22 assigns confidence to error-suppressed reads based on mutation context, fragment length and 23 tumour representation. This workflow combines a number of concepts in a novel approach in 24 order to quantify ctDNA with maximal sensitivity. 25 We applied INVARto plasma sequencing data from 45 patients with stage II-IV melanoma 26 and 26 healthy individuals. ctDNA was detected to 1 mutant molecule per million, and tu- 3 27 mour volumes of ~1cm .
    [Show full text]
  • Reddy to Become Lynn's Police Chief
    DEALS OF THE $DAY$ PG. 3 DEALS OF THE $DAY$ PG. 3 SATURDAY, MAY 15, 2021 DEALS OF THE Salem Reddy to become $LynnDAY$ PG. 3 group Lynn’s police chief updates brings By Elyse Carmosino long Lynner” who demonstrated ESL plan ITEM STAFF necessary skills to lead the depart- DEALS ment “with the highest standards” By Tréa Lavery LYNN — Christopher P. Reddy throughout his hiring process. OFITEM THE STAFF health will serve as chief of police for the “He has a deep understanding of City of Lynn, Mayor Thomas M. the Lynn community and the im- LYNN$DA — YSchool$ Su- McGee announced Friday. portance of racial equity in mod- perintendentPG. 3 Patrick to door Reddy, who will replace acting Po- ern policing by having built strong Tutwiler has proposed lice Chief Leonard Desmarais, was relationships with many diverse an updated plan for re- By Tréa Lavery selected from a list of several candi- groups and organizations during quiring ESL (English as ITEM STAFF dates who completed the required his time as a Lynn police officer,” a second language) li- Civil Service Assessment exam in McGee said. “Chris is ready to meet censes for kindergarten SALEM — The city’s March of this year. the moment and lead the hard- COURTESY PHOTO teachersDEALS in the district, newest outreach team He won the position over fellow working women and men of the extending the deadline Christopher Reddy, a life- OF THE has started working to finalists Capt. Mark O’Toole and Lynn Police Department through for certificationOF THE from two help residents access Deputy Chief Michael Vail.
    [Show full text]
  • Liquid Biopsy Is at the Core of Our Mission to Conquer Cancer with Data
    guardanthealth.com • [email protected] • +1.812.731.2203 CORPORATE BACKGROUNDER LIQUID BIOPSY IS AT THE CORE OF OUR MISSION TO CONQUER CANCER WITH DATA Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary blood tests, vast data sets, and advanced analytics. A company uniquely positioned to help patients across the entire cancer care continuum At Guardant Health, we believe liquid biopsy is at the center of transforming cancer care by unlocking data that will help patients at all stages of the disease. While we’ve made great strides to help advanced cancer patients, our vision since inception has been to detect cancer early, when patient survival rates can be impacted most. We are dedicated to helping patients across the cancer care continuum live longer, healthier lives. 700K+ 15M+ 65M+ Advanced Cancer Early-Stage Patients Asymptomatic and Patients and Survivors High Risk Screening Guardant360® CDx liquid biopsy LUNAR-1 program (in development) LUNAR-2 program (in development) (Estimated number of patients in the US) Guardant360® CDx liquid biopsy is poised to bring the promise of precision oncology to more patients Guardant360® CDx is the first FDA-approved liquid biopsy for comprehensive genomic profiling (CGP) in advanced cancer patients across all solid cancers, and for use as a companion diagnostic for patients who may benefit from Tagrisso® (osimertinib). We believe the ease of our blood test together with approval will help widen adoption of CGP and enable more patients to receive potentially life-changing precision medicines. In 2014, we introduced the Guardant360 laboratory developed test (LDT), the first-in-kind liquid biopsy to comprehensively sequence a patient's cancer to reveal actionable mutations.
    [Show full text]
  • Prospective Blinded Study of Somatic Mutation Detection in Cell-Free DNA Utilizing a Targeted 54-Gene Next Generation Sequencing
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 37 Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients Seung Tae Kim1,*, Won-Suk Lee2,*, Richard B. Lanman3, Stefanie Mortimer3, Oliver A. Zill3, Kyoung-Mee Kim4,5, Kee Taek Jang5, Seok-Hyung Kim5, Se Hoon Park1, Joon Oh Park1,4, Young Suk Park1, Ho Yeong Lim1, Helmy Eltoukhy3, Won Ki Kang1, Woo Yong Lee6, Hee-Cheol Kim6, Keunchil Park1,4, Jeeyun Lee1,4, AmirAli Talasaz3 1 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 2 Department of Surgery, Gil Medical Center, Gachon University, School of Medicine, Incheon, Korea 3 Guardant Health Inc., Redwood City, CA, USA 4 The Innovative Cancer Medicine Institute, Samsung Medical Center, Seoul, Korea 5 Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 6 Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea *These authors have contributed equally to this work Correspondence to: Jeeyun Lee, e-mail: [email protected] AmirAli Talasaz, e-mail: [email protected] Keywords: cell-free DNA (cfDNA), digital sequencing, genomic test Received: July 31, 2015 Accepted: September 24, 2015 Published: October 05, 2015 ABSTRACT Sequencing of the mutant allele fraction of circulating cell-free DNA (cfDNA) derived from tumors is increasingly utilized to detect actionable genomic alterations in cancer. We conducted a prospective blinded study of a comprehensive cfDNA sequencing panel with 54 cancer genes. To evaluate the concordance between cfDNA and tumor DNA (tDNA), sequencing results were compared between cfDNA from plasma and genomic tumor DNA (tDNA).
    [Show full text]
  • The Top 50 Healthcare Technology Ceos of 2021
    The Top 50 Healthcare Technology CEOs Of 2021 April 14, 2021 The Healthcare Technology Report is pleased to announce the Top 50 Healthcare Technology CEOs of 2021. This year’s awardees represent some of the most accomplished executives in healthcare technology. Their leadership has been critical in developing industry leading medical devices, next generation software platforms, cutting-edge drugs and therapeutics, and advanced diagnostics, among other technologies. Notably, in addition to overseeing their companies’ efforts from the C-suite, many of these leaders were also founders or co-founders of their organizations, recognizing unique opportunities for transformation and growth within their areas of expertise. From inventing novel orthopedic and mobility devices, to spearheading platforms to strengthen the patient/provider connection, and to developing new blood tests to diagnose diseases, these awardees have made significant contributions to society at large. They come from varied backgrounds in medicine, research, biotechnology, business, and finance, leveraging unique insights to provide their companies with the agility and ingenuity needed to thrive. While highly involved and instrumental to the continued success of their companies, they have also remained dedicated to advancing their particular fields, with many participating in prestigious research institutions and trade groups that are collaborating to develop more effective solutions for patients across the globe. Please join us in honoring The Top 50 Healthcare Technology CEOs of 2021. The Healthcare Technology Report https://thehealthcaretechnologyreport.com/the-top-50-healthcare-technology-ceos-of-2021/ 1. Geoff Martha Company: Medtronic Title: Chairman of the Board of Directors and Chief Executive Officer Geoff Martha is Chairman of the Board of Directors and Chief Executive Officer at Medtronic.
    [Show full text]
  • The Future of Genomic Medicine IX Thursday, March 3 and Friday, March 4, 2016 • Scripps Institution of Oceanography • La Jolla, California
    The Future of Genomic Medicine IX Thursday, March 3 and Friday, March 4, 2016 • Scripps Institution of Oceanography • La Jolla, California Presented in partnership with AAAS/Science Translational Medicine Course Introduction Conference Highlights • Voice of the patient represented Course Overview throughout the conference In collaboration with AAAS/Science Translational Medicine we invite you to • Renowned faculty representing the another exciting two day program on Thursday, March 3 and Friday, March country’s leading institutions • Multiple panel discussion segments 4, 2016 in beautiful San Diego, California. The 2016 program will again be with ample question and answer time with faculty held at Scripps Institution of Oceanography. • Additional networking opportunities The 9th Future of Genomic Medicine conference will be the next iteration Educational Objectives of taking genomic knowledge to transform the daily practice of medicine. After attending this activity, participants should be able to: To do this, we have patients present their story of how genomics affected • Demonstrate the unmet needs of their medical status, and have an international faculty of experts in genomics, medicine today with respect to more targeted, individualized prevention science and medical journalism, and the life science industry provide critical and treatments. perspective. This year we will be paying particular attention to the exciting • Discuss the opportunities of the genome, proteome, metabolome area of genomic editing to treat particular diseases, cancer (a disease of the discovery to change medical practice as it exists today. genome), and the genomics of rare and unknown diseases. Furthermore, we • Assess how changes and advances in will delve into to the hot topics of the microbiome, genomic-guided drug technology are rapidly ushering in a whole array of new pathways for therapies and genomic analytics.
    [Show full text]
  • Guardant Health Q3 2020 Earnings Call
    Guardant Health Third Quarter 2020 Earnings Call November 5, 2020 Guardant Health – Third Quarter 2020 Earnings Call, November 5, 2020 C O R P O R A T E P A R T I C I P A N T S Carrie Mendivil, Investor Relations - Gilmartin Group Helmy Eltoukhy, Co-founder and Chief Executive Officer AmirAli Talasaz, Co-founder and President Derek Bertocci, Chief Financial Officer C O N F E R E N C E C A L L P A R T I C I P A N T S Puneet Souda, SVB Tycho Peterson, JPMorgan Doug Schenkel, Cowen Derik de Bruin, Bank of America Brian Weinstein, William Blair Patrick Donnelly, Citigroup Tejas Savant, Morgan Stanley Sung Ji Nam, BTIG P R E S E N T A T I O N Operator Ladies and gentlemen, thank you for standing by, and welcome to the Guardant Health Q3 2020 Earnings Call. At this time all participants are in a listen-only-mode. After the speaker’s presentation, there will be a question-and-answer session. To ask a question during the session, you need to press star, one on your telephone. If you wish to withdraw your question, press the pound key. I would now like to turn the conference over to your speaker today, Carrie Mendivil with Investor Relations. You may begin. Carrie Mendivil 1 ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.
    [Show full text]